Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
US7618631B2 · kind B2 · utility
35Cited by
103References
28Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 16, 2005 |
| Grant date | Nov 17, 2009 |
| Priority date | — |
| Expiry date | Jun 7, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.